PPD

OCTOBER 17, 2024

Cell and gene therapy (CGT) studies are rapidly gaining momentum in the Asia-Pacific region, fueled by growing patient demand and a thriving ecosystem of innovation. In China, the high incidence of solid tumors is driving an urgent need for advanced therapies, spurring the push for new treatment approaches.

Therapies 97

Therapies Clinical Trials Clinical Research Trials 97

Drug Target Review

JULY 31, 2023

Our inaugural report is a groundbreaking exploration of the remarkable advancements in cell and gene therapy that are revolutionising the field of drug discovery. Expert Insights We are honoured to have collaborated with renowned experts in the field of cell and gene therapy, who have generously shared their invaluable insights.

Therapies 98

Therapies Disease Clinical Development Hospitals 98

Drugs.com

MARCH 25, 2024

MONDAY, March 25, 2024 — Men with prostate cancer treated at hospitals participating in a special drug-pricing program were more likely to stick to their therapy than patients elsewhere, new research reveals.The federal 340B Drug Program requires.

Treatment 147

Treatment Hospitals Therapies Research 147

Drug Target Review

NOVEMBER 17, 2023

They do not induce ‘graft versus host’ disease when transplanted for allogeneic therapy and there appears little sign of immune rejection. Peripheral blood NK cells have been used in allogeneic cancer therapies and shown to be safe. NK cells can be readily extracted from umbilical cord blood or peripheral blood of adult donors.

Therapies 103

Therapies Clinical Trials Immune Response Trials 103

DrugBank

JUNE 13, 2024

  Gene Therapy: Reprogramming the Body's Cellular Code    Gene therapy is an exciting field that treats diseases at their genetic roots.    A key part of gene therapy is efficiently delivering the therapeutic genetic material directly into target cells.

Therapies 98

Therapies Drugs DNA Treatment 98

SCIENMAG: Medicine & Health

JUNE 30, 2023

The study involved ArteraAI, a developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, and other researchers including those from University Hospitals (UH) Seidman Cancer Center. The information […]

Hospitals 85

Hospitals Research Therapies 85

SCIENMAG: Medicine & Health

JUNE 18, 2023

A three-year-long retrospective cohort study of a single Atlanta hospital’s patient population found transgender and gender-diverse teenagers rarely chose to discontinue gender-affirming hormone therapy, according to a study being presented Sunday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.

Therapies 62

Therapies Hospitals 62

Broad Institute

FEBRUARY 26, 2025

This study provides us with the data we need to create myeloid-targeting strategies to modulate these programs and make immunotherapies more effective for brain tumor patients, said Tyler Miller, co-first author on the study and a resident in clinical pathology at Massachusetts General Hospital when the study began.

Immune Response 132

Immune Response Treatment RNA Clinical Trials 132

Drug Target Review

FEBRUARY 1, 2024

Historically, what has limited investor interest in funding neurological and psychiatric therapies in development? Investors have historically taken a ‘guilty until proven innocent’ approach to investing in neuroscience therapies. All stakeholders have benefited from these innovations.

Therapies 104

Therapies Drug Development Disease Clinical Development 104

SCIENMAG: Medicine & Health

JULY 14, 2023

CLEVELAND – A new study from University Hospitals (UH) Connor Whole Health describes the scope and integration of their music therapy program within10 UH medical centers.

Therapies 66

Therapies Hospitals Research 66

Drug Discovery Today

MAY 21, 2020

Translational Programme established for FIH late stage HER2 positive breast cancer in Q4 2020

Hospitals 100

Hospitals Production Therapies 100

Conversations in Drug Development Trends

OCTOBER 14, 2024

Given the complexity and widespread impact of autoimmune and bone health conditions, developing new therapies is essential. These therapies represent a significant shift from traditional treatments, offering patients a higher chance of long-term symptom relief and improved quality of life.

Research 52

Research Clinical Trials Therapies Immune Response 52

SCIENMAG: Medicine & Health

JULY 21, 2023

The preclinical study showed that injecting ovarian tissue-derived differentiated induced pluripotent stem cells can restore hormone production and fertility in mice with premature ovarian failure related to genetic diseases and cancer treatment A new study by investigators from Brigham and Women’s Hospital, a founding members of the Mass General Brigham (..)

Therapies 80

Therapies Research Hospitals Treatment 80

Fierce BioTech

AUGUST 31, 2023

How Continuous Safety Monitoring Can Reduce Hospital Stays for High-Risk Oncology Patients swheeler Thu, 08/31/2023 - 14:13 Fri, 10/06/2023 - 14:00 Resource Type Webinar Sridevi Rajeeve, MD Nicole Zahradka, PhD Duration 45 Minutes Cellular therapy products such as CAR-T show promising clinical efficacy in fighting cancer.

Hospitals 52

Hospitals Therapies Production Research 52

Drug Channels

DECEMBER 19, 2021

Ring in 2022 with these noisemakers from the Drug Channels party bag: Hospitals earn incredible markups on CAR-T therapies Utilization management booms Health plans often ignore clinical guidelines Benefit designs flummox physicians Plus: an awesomely concise summary of U.S. Happy New Year, everyone! health insurance.

Hospitals 98

Hospitals Therapies Drugs 98

Drug Target Review

FEBRUARY 21, 2024

Stem cell transplants have saved patients’ lives time and time again, which led us to launch our own Stem Cell Transplant and Cellular Therapy Program. Regarding CAR-T cell therapy, could you highlight the promising findings that have been identified in the early stages of drug discovery, as well as potential challenges?

Therapies 64

Therapies Treatment Vaccine FDA Approval 64

KIF1A

APRIL 25, 2024

She is scheduled to be the 2nd patient in the world to receive ASO therapy for KAND. March 2023 – We met with n-Lorem and found out Susannah’s ASO (1st KAND patient to receive ASO therapy for KAND) would work for Sloane. Sloane is an adorable 3 year old with KAND. Hello KIF1A Community! We are also paying for our housing.

Therapies 52

Therapies FDA Approval FDA Treatment 52

Drug Target Review

AUGUST 29, 2024

What potential advantages does the CD5 modulation strategy offer over traditional CAR-T therapies? MR : Chimeric antigen receptor T-cell (CAR-T) therapy is very effective in treating patients with B-cell lymphoma, leukemia, and multiple myeloma, where we have six FDA-approved drugs.

Therapies 59

Therapies Treatment Engineering Molecular Biology 59

ASPET

AUGUST 2, 2024

Based on previous studies, we hypothesized that vascular senescence increases the risk of bleeding during warfarin therapy. Vascular senescence, marked by vascular stiffening and endothelial dysfunction, has an unclear effect on the efficacy and safety of warfarin.

Therapies 100

Therapies Hospitals International 100

Drug Target Review

SEPTEMBER 6, 2024

What trends are driving the increased use of in vivo delivery methods in gene therapy? Generally, the amount of lentiviral vector that is used for in vivo gene therapy is larger than for ex vivo use. How are new therapeutic areas emerging as potential targets for in vivo gene therapy?

Therapies 59

Therapies Vaccine Marketing Disease 59

The Pharma Data

APRIL 8, 2021

These important findings advance our pursuit of treatment options to save lives in hospitalized COVID-19 patients.” European Union and other geographies to evaluate next steps for baricitinib for the treatment of hospitalized COVID-19 patients. and 14.7%, respectively) and placebo (44.4% and 18.0%, respectively) groups.

Hospitals 52

Hospitals FDA Approval Laboratories Treatment 52

Broad Institute

AUGUST 19, 2024

Jude Children’s Research Hospital have discovered that oleic acid, one of the most abundant fatty acids in the body, restores a healthy balance of vaginal microbes in a laboratory model of BV. Jude Children’s Research Hospital, the Bill & Melinda Gates Foundation, and other sources. Paper cited Zhu M et al.

Hospitals 121

Hospitals Treatment Medical Schools Science 121

Broad Institute

AUGUST 7, 2024

Core institute members have a major research presence at Broad, and remain full members of their home institution (MIT, Harvard University, or one of Harvard’s primary teaching hospitals). She is a professor of medicine at Harvard Medical School and Brigham and Women’s Hospital, and a member of the Broad’s Executive Leadership Team.

Medical Schools 90

Medical Schools Hospitals Bioinformatics Vaccine 90

The Pharma Data

SEPTEMBER 11, 2021

– Designation is based on results from the EMPEROR-Preserved phase III trial, which established Jardiance as the first therapy to show statistically significant improvement in heart failure outcomes in adults with heart failure with preserved ejection fraction. The benefit was independent of ejection fraction or diabetes status.

Therapies 52

Therapies FDA Hospitals FDA Approval 52

The Pharma Data

SEPTEMBER 11, 2021

Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for empagliflozin as an investigational treatment for adults with heart failure with preserved ejection fraction (HFpEF), Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced. 2,3 A leading cause of hospitalization in the U.S.

Therapies 52

Therapies Hospitals Clinical Trials Trials 52

The Pharma Data

APRIL 19, 2022

Kite’s Global CAR T-Cell Therapy Manufacturing Network Increasing Capacity by 50% to Meet Patient Demand for New Cancer Therapies. — Scalable and Adaptable Facility Provides Flexibility for Current and Future Cell Therapy Innovation. The site will produce Kite’s FDA approved CAR T-cell therapy used to treat blood cancer.

FDA Approval 52

FDA Approval Therapies FDA Hospitals 52

The Pharma Data

AUGUST 30, 2021

In this clinical first for adults with heart failure with preserved ejection fraction, empagliflozin demonstrated an impressive 21 percent relative risk reduction in the composite primary endpoint of cardiovascular death or hospitalization for heart failure 1. EMPEROR-Preserved included 5,988 people with heart failure.

Trials 52

Trials Therapies Hospitals Treatment 52

Drug Target Review

DECEMBER 16, 2024

This field allowed me the privilege of tending to children in the hospital and building long-term relationships with them and their families. Throughout her academic career, she worked in translational and clinical research, focusing on novel therapies for pediatric cancers.

Medical Schools 52

Medical Schools Clinical Research Drug Development Trials 52

SCIENMAG: Medicine & Health

JUNE 14, 2023

Three young patients with relapsed T-cell leukaemia have now been treated with base-edited T-cells, as part of a ‘bench-to-bedside’ collaboration between UCL and Great Ormond Street Hospital for Children (GOSH).

Therapies 58

Therapies Clinical Trials Hospitals Trials 58

The Pharma Data

SEPTEMBER 27, 2021

Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for empagliflozin as an investigational treatment for adults with coronary failure with preserved ejection fraction (HFpEF), Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced. 2,3 a number one explanation for hospitalization within the U.S.

Therapies 52

Therapies Clinical Trials Hospitals Trials 52

Broad Institute

FEBRUARY 7, 2024

It examined endothelial mechanisms unrelated to lipid metabolism (a known driver of CAD risk with effective therapies, like statins) in hopes of uncovering other mechanisms driving CAD risk for which therapies may yet be developed. “Now

Disease 105

Disease Hospitals Medical Schools Therapies 105

Drug Target Review

JANUARY 12, 2024

This one size fits all approach to drug prescribing still pervades in mostly all therapy areas except oncology. Therefore, having biomarker information is useful for separating individuals and ensuring that you treat an individual as an individual and can tailor their therapy. Most drugs do not work in all people.

Doctors 111

Doctors Clinical Trials Treatment Therapies 111

Drug Target Review

JANUARY 23, 2024

Cell-based therapies, such as tumour-infiltrating lymphocyte (TIL) therapy, have also drawn significant attention following promising results in a melanoma trial. We anticipate this area to grow, especially cancer vaccines, with important read-outs expected across various cancer types in 2024.

Treatment 122

Treatment Immune Response Vaccine Therapies 122

SCIENMAG: Medicine & Health

JULY 5, 2023

New insights explaining why some children have a longer remission than others after having cutting-edge CAR T-cell therapy for leukaemia have been revealed by researchers at UCL, Great Ormond Street Hospital, and the Wellcome Sanger Institute.

Treatment 69

Treatment Hospitals Therapies Research 69

Broad Institute

JUNE 1, 2023

“This is potentially an ideal use case for polygenic risk scores to refine risk assessment,” said Michael Honigberg , a co-first author on the study, associate member at the Broad, and a cardiologist at Massachusetts General Hospital.

Doctors 133

Doctors Medical Schools Hospitals DNA 133

Broad Institute

MARCH 8, 2024

Also, the genetic mechanisms of disease that we have identified offer the potential to guide development of curative therapies,” added co–lead author Aaron Deutsch, an instructor in the division of Endocrinology at MGH.

Medical Schools 127

Medical Schools Hospitals Disease Therapies 127

The Pharma Data

JULY 29, 2021

The EUA now provides for the use of baricitinib for treatment of COVID-19 in hospitalized adults and pediatric patients two years of age or older requiring supplemental oxygen, non-invasive or invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO). percent (24/515) for baricitinib plus remdesivir versus 7.1

Hospitals 52

Hospitals FDA Laboratories Treatment 52